Skip to content
Open access

Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.

Sep 2026 · Strahlentherapie und Onkologie (Print) · 0 citations · 27 references
Medicine

TL;DR

HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.

Abstract

Purpose

For elderly and frail patients with rectal cancer, unfit for radical surgery or extensive chemoradiation schedules, radiotherapy dose escalation by use of high-dose-rate brachytherapy (HDR-BT) may be an alternative organ-preserving approach.

Methods

15 elderly/frail patients (median age, 83 years; ECOG 1‑2: 80%) with histologically confirmed rectal adenocarcinoma (T1-3, N0-1, M0; UICC stage I-IIIB) were treated with definitive radiotherapy consisting of external beam radiation therapy (EBRT) of 30-39 Gy in 10-13 fractions, followed by image-guided endorectal HDR-BT with 12-24 Gy in 2-3 fractions. Acute and late toxicity of combined EBRT and HDR-BT was recorded according to CTCAE v5.0. Initial tumor response (clinical complete response, cCR, near clinical complete response, ncCR, and incomplete response, IR) and long-term disease control were assessed using clinical examination, endoscopy, and magnetic resonance imaging.

Results

Median follow-up was 21 (range, 9-43) months. Six weeks after completion of EBRT + HDR-BT, cCR (n = 6) or ncCR (n = 6) was confirmed in 12/15 patients (80%), 3 patients (20%) had IR. Local regrowth after initial (n)cCR was observed in 4 patients (33%). A total of 4/15 patients (27%) developed distant metastases (2 with IR, 2 with (n)cCR). Most common acute toxicities were mild/moderate proctitis (grade 1-2) in 67%, and mild grade 2 cystitis in 27%. Three patients (20%), of whom two were receiving oral anticoagulation, experienced late grade 3 rectal bleeding, requiring blood transfusion. One patient developed grade 3 rectal ulcer with necrosis treated with rectal amputation.

Conclusions

HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control. The incidence of late grade 3 rectal bleeding, especially in patients receiving concomitant oral anticoagulation, requires careful patient selection, and further dose and treatment optimization (as implemented in the upcoming ACO/ARO/AIO-22 trial).

Read PDF

Similar papers

Sep 2026

High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients.

OBJECTIVE To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification. METHODS AND MATERIALS We retrospectively analyzed 607 (2012-2023) men t...

M. Choudhury, F. Adeoye, S. Nageshwaran et al. · 0 citations
Open access Oct 2026

Definitive Hypofractionated Simultaneous Integrated Boost Intensity-modulated Radiotherapy (60 Gy in 25 Fractions) in Elderly Patients with Locally Advanced Head and Neck Cancer Ineligible for Concurrent Chemotherapy: A Prospective, Single-arm Feasibility Study

A BSTRACT Elderly patients with head and neck squamous cell carcinoma (HNSCC) often cannot tolerate prolonged conventional radiotherapy and are under-represented in trials. As the meta-analysis of chemotherapy in head and neck cancer meta-analysis shows the benefit of concurrent chemotherapy diminishes with a...

M. S. Pranav, G. Vydia, Ramanaiah Kaluvoya · 0 citations
Review Oct 2026

Safety and early outcomes of external beam radiation therapy with low dose brachytherapy boost in patients with prostate cancer: A single institution experience.

Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.

Z. El Kouzi, M. Rooney, Adam B. Samman et al. · 0 citations
Open access Sep 2026

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.

Valeria Epifani, P. Anselmo, F. Arcidiacono et al. · 0 citations
Oct 2026

Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.

DE-fsHDR is a safe and effective salvage treatment for IPR and GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.

A. Solanki, William Adams, James A. Proudfoot et al. · 0 citations
Open access Sep 2026

Long-term outcomes of high-dose hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.

High-dose hyperfractionated radiotherapy may be a feasible dose-escalated option for patients with LS-SCLC, with acceptable toxicity, with published data on the long-term outcomes of this specific regimen.

Yasuhito Hagiwara, Yuuki Kuroda, Kenji Takai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.